Evidence map›Paper›PMID 29492199›Full record

ArticleOncotarget2018

The mutational landscape of

Bram De Wilde, Anneleen Beckers, Sven Lindner, Althoff Kristina, Katleen De Preter, Pauline Depuydt, Pieter Mestdagh, Tom Sante, Steve Lefever, Falk Hertwig and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bram De WildeCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Anneleen BeckersCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Sven LindnerDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Essen, Germany.
Althoff KristinaDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Essen, Germany.
Katleen De PreterCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Pauline DepuydtCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Pieter MestdaghCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Tom SanteCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Steve LefeverCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Falk HertwigDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Cologne, Germany.
Zhiyu PengBGI-Shenzhen, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong, China.
Le-Ming ShiCenter for Pharmacogenomics and Fudan-Zhangjiang Center for Clinical Genomics, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China.
Sangkyun LeeDepartment of Computer Science, Artificial Intelligence Group, TU Dortmund, Dortmund, Germany.
Elien VandermarliereMedical Biotechnology Center, VIB, Ghent, Belgium.
Lennart MartensMedical Biotechnology Center, VIB, Ghent, Belgium.
Björn MentenCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Alexander SchrammDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Essen, Germany.
Matthias FischerDepartment of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Cologne, Germany.
Johannes SchultePediatric Oncology and Hematology, Charité University Medicine, Berlin, Germany.
Jo VandesompeleCenter for Medical Genetics, Ghent University, Ghent, Belgium.
Frank SpelemanCenter for Medical Genetics, Ghent University, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically engineered mouse models have proven to be essential tools for unraveling fundamental aspects of cancer biology and for testing novel therapeutic strategies. To optimally serve these goals, it is essential that the mouse model faithfully recapitulates the human disease. Recently, novel mouse models for neuroblastoma have been developed. Here, we report on the further genomic characterization through exome sequencing and DNA copy number analysis of four of the currently available murine neuroblastoma model systems (

Indexed as

array CGHexome sequencingmouse modelneuroblastoma

Identifiers

PMID29492199
PMCPMC5823580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.